Abbott Laboratories (ABT) Downgraded to Hold by Argus Research

Market Context

Abbott Laboratories operates in the Healthcare sector. The stock currently trades at $103.10 with a market capitalization of $202.5B. The stock has declined 15.6% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Argus Research's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Abbott Laboratories

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 27, 2026	Argus Research	Hold	N/A
Oct 23, 2026	Wells Fargo	Overweight	N/A
Oct 22, 2026	JP Morgan	Overweight	N/A
Oct 22, 2026	Baird	Outperform	N/A
Oct 22, 2026	TD Cowen	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View ABT Stock Page